
    
      The study design includes backbone of 10 weeks of preoperative therapy using MAP (high-dose
      methotrexate, cisplatin, doxorubicin and dexrazoxane). Metastatic patients were randomized to
      high-dose chemotherapy for 31 weeks (arm 1) or concomitant metronomic therapy (MTX plus
      cyclophosphamide) such as 31 weeks of high-dose chemotherapy, followed by 73 weeks of
      metronomic therapy after completion of high-dose chemotherapy, totaling 104 weeks of
      metronomic therapy (arm 2).
    
  